Rocket Pharmaceuticals Inc
Closed
SectorHealthcare
3.6 2.27
Overview
Share price change
24h
Min
3.54
Max
3.6
Income | -5.1M -48M |
|---|---|
EPS | -0.42 |
Employees | 202 |
EBITDA | -8M -45M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +199.17% upside |
Next Earnings | 12 Aug 2026 |
|---|
Market Cap | -22M 372M |
|---|---|
Previous open | 1.33 |
Previous close | 3.6 |
Rocket Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Rocket Pharmaceuticals Inc Forecast
Price Target
By TipRanks
199.17% upside
12 Months Forecast
Average 10.8 USD 199.17%
High 16 USD
Low 5 USD
Based on 6 Wall Street analysts offering 12 month price targets forRocket Pharmaceuticals Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
